ArcherDX files for $100M IPO as it plans to submit flagship test to FDA

BOULDER— ArcherDX Inc. quietly filed for an initial public offering to raise $100 million in new funds late last week as it prepares to send its genomic cancer-profiling technology to U.S. regulators later this year.

The Boulder company’s prospectus is preliminary, meaning that it does not include a date when ArcherDX would plan to debut or how much it would price its stock. It intends to list on the Nasdaq under the ticker symbol RCHR.

However, the maximum amount of funding it could raise as proposed is $100 million, with the principal goal being development and…